Physician profile
Stepanida Freeman
NPI 1043502446
$18,152.28
in general payments reported to CMS, 2019-2025
39 companies · $424 in 2025
The $424 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $1,801 · 2021: $620 · 2022: $630 · 2023: $819 · 2024: $13K · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $12K · Food and Beverage: $2,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $12,090.95 |
| Food and Beverage | $2,142.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $13,951.23 | 2020-2024 | |
| Abbvie INC. | $875.81 | 2019-2024 | |
| Daiichi Sankyo INC. | $475.31 | 2019-2025 | Injectafer |
| Astellas Pharma US INC | $288.12 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $238.47 | 2022-2025 | |
| Amgen INC. | $208.67 | 2019-2020 | |
| Pfizer INC. | $188.39 | 2020-2024 | |
| Exeltis, USA INC. | $158.63 | 2020-2025 | Slynd |
| Hologic Sales and Service, LLC | $126.94 | 2021-2025 | Aptima |
| Radius Health, INC. | $124.95 | 2019 | |
| Gilead Sciences, INC. | $124.40 | 2019 | |
| Therapeuticsmd, INC. | $121.15 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.56 | 2021-2025 | |
| Melinta Therapeutics, LLC | $107.38 | 2019 | |
| Sumitomo Pharma America, INC. | $96.48 | 2023-2025 | Myfembree |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $94.57 | 2021-2024 | Nexplanon |
| Coopersurgical, INC. | $87.21 | 2019-2024 | Paragard T 380a |
| Evofem Biosciences, INC. | $76.86 | 2022 | |
| Avion Pharmaceuticals | $70.37 | 2019-2023 | Balcoltra |
| Sage Therapeutics, LLC | $68.37 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $58.61 | 2021-2022 | |
| Exact Sciences Corporation | $54.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Agile Therapeutics, INC. | $52.67 | 2021-2023 | Twirla |
| Myriad Women'S Health, INC. | $48.13 | 2023 | Myrisk |
| Minerva Surgical, INC | $42.71 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $38.43 | 2019-2023 | Gardasil 9 |
| Mylan Pharmaceuticals INC. | $33.89 | 2021 | |
| Allergan, INC. | $28.16 | 2019 | |
| Aspira Women'S Health INC | $25.86 | 2024 | Ova1 |
| Becton, Dickinson and Company | $23.45 | 2023 | Bd Onclarity |
| Mission Pharmacal Company | $23.12 | 2019 | |
| Dexcom, INC. | $18.49 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $17.83 | 2025 | |
| Vertical Pharmaceuticals, LLC | $17.40 | 2019 | |
| Dysis Medical, INC. | $17.10 | 2022 | |
| Millicent US INC | $16.76 | 2025 | Femlyv |
| Lupin INC. | $16.01 | 2019 | |
| Olympus America INC. | $12.83 | 2023 | |
| Microline Surgical INC | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stepanida Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.